Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4 : A Nested Case–Control Study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Eugene Jeong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Me…. Hauptthemen laut MEDLINE: Omeprazole, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP3A, Muscular Diseases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NLM NIH HHS, U.S. National Library of Medicine of the National Institutes of Health.
Abstract (Originalsprache)
Background
Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
Aims
This study leveraged electronic health record (EHR) and biobank data to validate an interaction between omeprazole and fluconazole and to explore drug–gene interactions (DGIs) between omeprazole and polymorphisms in CYP enzymes. Materials and Methods A nested case–control design with incidence‐density matching was used. Cases were defined as patients who developed myopathy during ongoing omeprazole therapy. For each case, up to four controls were selected from patients who had not developed myopathy by the time the case was diagnosed. Conditional logistic regression models, adjusting for relevant covariates, evaluated (i) the association between concomitant fluconazole use and myopathy and (ii) genotype‐stratified myopathy risk.
Results
Among 902 cases and 3608 controls, the combined use of omeprazole and fluconazole was linked to an increased risk of myopathy (adjusted odds ratio [AOR] = 1.75, 95% confidence interval [CI]: 1.17–2.63, p = 0.007). In the DGI analysis, which included 862 cases and 3448 controls, individuals classified as CYP2C19 poor metabolizers paired with CYP3A4 extensive metabolizers showed a significantly higher myopathy risk (AOR = 1.62, 95% CI: 1.03–2.55, p = 0.036); those with CYP2C19 poor metabolizer/CYP3A4 intermediate metabolizer had an even greater risk (AOR = 4.77, 95% CI: 1.74–13.1, p = 0.002).
Discussion
These findings not only confirm previously reported drug–drug interactions (DDIs) between omeprazole and fluconazole but also reveal the emerging clinical implications of DGIs.
Conclusion
By integrating EHR and genetic data, the study showcases how informatics tools can translate DDI findings into DGI hypotheses, effectively bridging genetic insights and clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Computer Science and Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.
- Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Computer Science, School of Engineering, Vanderbilt University, Nashville, Tennessee, USA.
ORCID-Profile: Eugene Jeong, Aditi Shendre, Yu Su, Xingyi Guo, Lang Li, You Chen
Förderung
- NCI NIH HHS
- NLM NIH HHS
- U.S. National Library of Medicine of the National Institutes of Health
- NCATS NIH HHS
- National Center for Advancing Translational Sciences of the National Institutes of Health
- National Cancer Institute of the National Institutes of Health
- U.S. National Library of Medicine
- National Center for Advancing Translational Sciences
Zitieren
APA
Jeong, E., Shendre, A., Su, Y., Guo, X., Li, L., & Chen, Y. (2025). Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4 : A Nested Case–Control Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70058
Vancouver
Jeong E, Shendre A, Su Y, Guo X, Li L, Chen Y. Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4 : A Nested Case–Control Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70058
BibTeX
@article{Jeong2025,
author = {Jeong, Eugene and Shendre, Aditi and Su, Yu and Guo, Xingyi and Li, Lang and Chen, You},
title = {Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4 : A Nested Case–Control Study},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70058}
}
EUVIMED